Thompson Investment Management Inc. Has $889,000 Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Thompson Investment Management Inc. lifted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 8.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,220 shares of the specialty pharmaceutical company’s stock after purchasing an additional 550 shares during the period. Thompson Investment Management Inc.’s holdings in Jazz Pharmaceuticals were worth $889,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Pacer Advisors Inc. increased its holdings in shares of Jazz Pharmaceuticals by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock valued at $272,713,000 after purchasing an additional 115,102 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after acquiring an additional 48,708 shares during the last quarter. Thompson Siegel & Walmsley LLC raised its position in shares of Jazz Pharmaceuticals by 8.3% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 781,215 shares of the specialty pharmaceutical company’s stock valued at $87,035,000 after acquiring an additional 59,685 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Jazz Pharmaceuticals by 8.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 531,710 shares of the specialty pharmaceutical company’s stock valued at $59,238,000 after acquiring an additional 42,587 shares during the last quarter. Finally, Wedge Capital Management L L P NC bought a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at $32,497,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at $52,522,550.75. This represents a 0.35 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 5,053 shares of company stock worth $617,442 in the last three months. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $120.29 on Friday. The firm has a market cap of $7.27 billion, a PE ratio of 16.94, a PEG ratio of 0.92 and a beta of 0.56. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17. The company has a fifty day moving average price of $122.52 and a 200 day moving average price of $116.42.

Analyst Ratings Changes

Several analysts have commented on the stock. Needham & Company LLC reiterated a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. TD Cowen dropped their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Finally, Robert W. Baird boosted their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $177.00.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.